Don't know the answer but it's a great question.

Also, how does the "US-only HIV licensing agreement" deal with revenue generated by off-label use prior to the time CYDY gets approval for cancer (if ever)? I can think of a number of ways to deal with that, and it's an interesting question, to me anyway, from a drafting/lawyer standpoint....